XML 146 R100.htm IDEA: XBRL DOCUMENT v3.24.0.1
Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details) - EUR (€)
€ in Millions
Feb. 08, 2022
Sep. 14, 2021
Amunix Pharmaceuticals, Inc    
Disclosure of detailed information about business combination [line items]    
Other intangible assets € 493  
Other current and non-current assets and liabilities (13)  
Cash and cash equivalents 118  
Deferred taxes, net (81)  
Net assets 517  
Goodwill 609  
Purchase price € 1,126  
Translate Bio    
Disclosure of detailed information about business combination [line items]    
Other intangible assets   € 396
Other current and non-current assets and liabilities   235
Cash and cash equivalents   247
Deferred taxes, net   (93)
Contingent consideration liability   (323)
Net assets   462
Goodwill   2,118
Purchase price   € 2,580